Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors
Zura Bio (NASDAQ:ZURA) is now covered by analysts at Wedbush. They set an "outperform" rating and a $15.00 price target on the stock.